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Abstract
Purpose The prostate-specific membrane antigen (PSMA)
targeted positron-emitting-tomography (PET) tracer 68Ga-
PSMA-11 shows great promise in the detection of prostate can-
cer. However, 68Ga has several shortcomings as a radiolabel
including short half-life and non-ideal energies, and this has mo-
tivated consideration of 18F-labelled analogs. 18F-PSMA-1007
Methods Radiation dosimetry of F-PSMA-1007 was deter-
mined in three healthy volunteers who underwent whole-body
PET-scans and concomitant blood and urine sampling.
Following this, ten patients with high-risk prostate cancer
underwent 18F-PSMA-1007 PET/CT (1 h and 3 h p.i.) and nor-
mal organ biodistribution and tumor uptakes were examined.
Eight patients underwent prostatectomy with extended pelvic
lymphadenectomy. Uptake in intra-prostatic lesions and lymph
node metastases were correlated with final histopathology, in-
cluding PSMA immunostaining.
Results With an effective dose of approximately 4.4–5.5 mSv
per 200–250 MBq examination, 18F-PSMA-1007 behaves sim-
ilar to other PSMA-PET agents as well as to other 18F-labelled
PET-tracers. In comparison to other PSMA-targeting PET-
tracers, 18F-PSMA-1007 has reduced urinary clearance enabling
excellent assessment of the prostate. Similar to 18F-DCFPyL and
with slightly slower clearance kinetics than PSMA-11, favorable
tumor-to-background ratios are observed 2–3 h after injection. In
eight patients, diagnostic findings were successfully validated by
histopathology. 18F-PSMA-1007 PET/CT detected 18 of 19
lymph node metastases in the pelvis, including nodes as small
as 1 mm in diameter.
Conclusion 18F-PSMA-1007 performs at least comparably to
68Ga-PSMA-11, but its longer half-life combined with its su-
perior energy characteristics and non-urinary excretion over-
comes some practical limitations of 68Ga-labelled PSMA-
targeted tracers.
Keywords 18F-PSMA . F-18-PSMA . PSMA-1007 . PET/
CT . Positron emission tomography
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compounds because it demonstrated high labelling yields, out-
standing tumor uptake and fast, non-urinary background clear-
ance. Here, we describe the properties of 18F-PSMA-1007 in
human volunteers and patients.
was selected among several 18F-PSMA-ligand candidate
18
Introduction
The introduction of the 68Ga-labelled prostate-specific mem-
brane antigen (PSMA) targeted positron-emitting-tomogra-
phy/computed-tomography (PET/CT) tracer Glu-urea-
Lys(Ahx)-HBED-CC (PSMA-11) has proven highly sensitive
for the detection of disseminated prostate cancer (PCa). In two
studies (involving 319 patients and 248 patients, respectively)
sites of biochemical recurrence (BCR) were localized in 90 %
of patients including those with modest elevations in prostate
specific antigen (PSA) [1, 2]. PSMA-11 PET/CT appears su-
perior in sensitivity to other PETagents such as Choline-PET/
CT [3, 4]. This high sensitivity could have significant clinical
implications for modifications of treatment at various stages of
prostate cancer ranging from initial diagnosis to treatment
monitoring of castration resistant metastases. For instance,
68Ga-PSMA-11 PET/CT had a significant impact on radio-
therapy planning, resulting in meaningful changes in treat-
ment planning in over 50 % of patients [5, 6]. Although ex-
tensively studied in the recurrence and metastatic setting, there
has been relatively little attention paid to the use of PSMA-
PET in initial staging [7–10]. One challenge of 68Ga-PSMA-
11 imaging is that the agent is rapidly excreted via the urinary
tract resulting in intense accumulation in the bladder, thus,
obscuring the prostate. This has resulted in the development
of other agents with slower urinary excretion. One such can-
didate, 99mTc-MIP-1404, has been chosen for evaluation in
phase-2 (NCT01667536) and phase-3 (NCT02615067) stud-
ies in North America for primary staging of PCa [11].
However, 99mTc is a single photon emitter and thus, has nei-
ther the sensitivity nor can gain the spatial resolution of PET-
based agents. Another challenge for 68Ga-PSMA-11 PET/CT
is the limited availability of the 68Ga via local radionuclide
generators. Each generator provides only one or two elutions
per day and is not only a substantial upfront investment but
requires separate syntheses at different times of the day in a
local radiopharmacy. Compared to 18F (0.65 MeV), the posi-
tron energy of 68Ga is higher (1.90 MeV), reducing the theo-
retical maximum spatial resolution [12]. Finally, the short
half-life of 68Ga relative to 18F, (68 vs. 110 min) limits the
ability to produce agents in a central facility and ship them to
distributed imaging centers.
The first generation of 18F-labelled PSMA-ligands, such as
18F-DCFBC, suffered from high background due to slow
blood clearance [13]. This has recently been addressed with
the introduction of the second generation compound 18F-
DCFPyL [14], a ligand which is characterized by fast elimi-
nation via the urinary route. However, neither 18F-DCFBC nor
18F-DCFPyL includes a chelator capable of binding therapeu-
tic nuclides. PSMA-617 includes a chelator for labeling with
diagnostic 68Ga as well as β-emitting 177Lu [15, 16] or α-
emitting 225Ac [17]. Here, we present initial data on the
biodistribution, radiation dosimetry and efficacy of 18F-
PSMA-1007, a new 18F-labelled PSMA-ligand structurally
related to PSMA-617 (Fig. 1) [18].
Material and methods
Synthesis and quality control of 18F-PSMA-1007
The non-radioactive reference compound 19F-PSMA-1007
and the PSMA-1007 precursor were synthesized using solid
phase chemistry [19]. 18F-PSMA-1007 was produced on an
automated synthesis module (Trasis AllInOne) in a two-step
synthesis using the prosthetic group 6-[18F]F-Py-TFP [20] for
Fig. 1 Comparison of different PSMA-ligands (18F-DCFBC, 18F-DCFPyL, 68Ga-PSMA-617, 68Ga-PSMA-11, 18F-PSMA-1007)
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coupling the PSMA-1007 precursor, and this was purified by
semi-preparative HPLC. The detailed description of the
radiolabelling process was published elsewhere [21]. A direct
radiofluorination method is being developed. Radio-HPLC
was performed to determine the chemical identity and the
chemical and radiochemical purity of 18F-PSMA-1007. The
chemical structure of 18F-PSMA-1007 is presented in Fig. 1.
Residual solvents were determined by gas chromatography.
Radionuclide purity was controlled by half-life measurement.
Integrity of the sterile filter after filtration was assessed using
the bubble-point test. The product solution was tested for ste-
rility, bacterial endotoxins (LAL-test), pH, colorlessness and
particles.
PET/CT-imaging
All imaging was performed on a Biograph mCT Flow scanner
(Siemens, Erlangen, Germany). PET was acquired in 3-D
mode (matrix 200 × 200) using FlowMotion (Siemens). The
emission data was corrected for randoms, scatter and decay.
Reconstruction was performed with an ordered subset expec-
tation maximization (OSEM) algorithm with two iterations/21
subsets and Gauss-filtered to a transaxial resolution of 5 mm at
full-width at half-maximum (FWHM); Attenuation correction
was performed using the unenhanced low-dose CT data. The
CT-scans were reconstructed to a slice thickness of 5 mm,
increment of 3–4 mm, soft tissue reconstruction kernel
(B30), using CareDose (Siemens).
Volunteers and patients
To determine initial dosimetry, three healthy volunteers
(normal PSA) underwent 18F-PSMA-1007 PET/CT with
scans obtained at multiple time points up to 6 h p.i. The
healthy subjects were imaged in three blocks. Block 1
began at PET-1 (start 5 min p.i.) and extended to PET-7
(ending 140 min p.i.), block 2 began at PET-8 (start
180 min p.i.) and extended to PET-9 (240–270 min p.i.)
and block 3 began at PET-10 (440–480 min p.i.). A non-
enhanced low-dose CT (estimate 1.4 mSv, respectively)
for attenuation correction was performed at the beginning
of each block, followed by serial emission scans without
moving the volunteers in between.
All patients (n = 10) gave written informed consent to
receive 18F-PSMA-1007 following guidelines of the
German Pharmaceuticals Act §13(2b). All patients had
newly diagnosed high-risk prostate cancer (median PSA-
level 14 ng/ml; range 5.8–87.3 ng/ml) with a median age
of 65 years (range 55–77) and underwent 18F-PSMA-
1007 PET/CT imaging 1 and 3 h post injection. The at-
tenuation correction CTs were also performed 1 and 3 h
post tracer injection. All men were treated clinically with
a multimodal approach and eight men underwent radical
prostatectomy with extended pelvic lymphadenectomy.
Two patients who were found to have metastatic disease
did not undergo prostatectomy. The data were analyzed
retrospectively with approval of the local ethics commit-
tee. Detailed patient characteristics and final histopatho-
logical evaluation are provided in Table 1.
Radiation dosimetry
The dosimetry analysis was performed using the QDOSE do-
simetry software suite (ABX-CRO, Germany). Automatic rig-
id co-registration and, if necessary, additional manual correc-
tion, were performed for all PET and CT data-sets. Kidneys,

















1 77 356 MBq 9 40.0 pT3b, pN1 (4/41), L1, V0,
Pn1
5 54.94 76.24
2 72 347 MBq 9 15.3 cT3b, cN1, cM1 7 47.71 74.11
3 55 315 MBq 9 14.0 pT3b, pN1 (5/40), L1, V0,
Pn1
4 10.92 14.84
4 65 301 MBq 9 13.9 pT3b, pN1 (4/43), L0, V0,
Pn1
4 24.30 30.18
5 64 331 MBq 9 10.0 pT3b, pN1 (3/48 LK), L1,
V0, Pn1
3 18.85 27.49
6 64 240 MBq 7 12.2 pT3a, pN1 (3/57), L1, V1,
Pn1
3 12.98 22.57
7 62 139 MBq 8 8.5 pT3a, pN0 (0/21), L0, V0,
Pn1
0 15.53 27.45
8 69 319 MBq 8 5.8 pT3a, pN0 (0/32), L0, V0,
Pn0
0 36.69 58.56
9 61 289 MBq 7 87.3 cT3, cN1, cM1 3 35.40 58.22
10 73 111 MBq 7 31.0 pT3a, pN0 (0/27), L0, V0,
Pn1
0 16.31 19.61
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liver, spleen, whole heart, upper and lower large intestine,
parotid glands, submandibular glands and urinary bladder
were segmented into volumes of interest (VOIs) using a per-
centage of maximum threshold between 20 and 30 % and the
corresponding CT as guidance. Afterwards the time activity
curves (TACs) were calculated for all organs. The TACs for
red marrow were derived from venous blood samples, and the
red marrow dose was calculated as described previously [22,
23]. The urinary bladder TACwas a combination of estimated
activity in the urinary bladder VOI in PET and measured ac-
tivity of voided urine. Curve fitting was applied to all TACs
according to the software. Kidneys, salivary glands, upper and
lower large intestine and heart were fitted with a bi-
exponential function. For liver, spleen and urinary bladder
content, a mono-exponential fit to the last three time points
was performed.
The cumulative activity Ã between time 0 and the first
measured time point was calculated assuming a linear increase
from 0 to the first measured activity. The Ã between the first
measured time point and the last measured time point was
integrated numerically using trapezoidal approximation. The
Ã from the last measured time point to infinity was integrated
using the fitted function. The total body Ã was calculated
based on the injected activity assuming only physical decay
neglecting the voided urine. The Ã of the remainder of the
body was then automatically calculated by subtracting all
source organs from the total body activity. All source organ
residence times were calculated by dividing the Ã by the
injected activity.
Absorbed and effective dose calculations were performed
using the ICRP endorsed IDAC 1.0 package [24] which is
integrated into QDOSE. In addition, residence times of all
source organs and the remainder of the body were exported
as an OLINDA case file for dose calculation in OLINDA 1.1
[25]. The absorbed doses to the salivary glands and prostate
were determined using the spherical model [26]. The organ
masses for the salivary glands were taken from ICRP publi-
cation 89 [27] with 25 g estimated weight for the parotid and
12.5 g for the submandibular gland.
Biodistribution
During the dosimetry evaluation, urine was collected at the
following intervals: 0–2 h, 2–4 h, and 4–6 h. Venous blood
samples were obtained at 2, 5, 10, 15, 30, 45, 60, 80, 120, 180,
240, and 360 min post injection. After the whole blood was
sampled, the remaining volume was centrifuged and serum
was extracted. Serum activities were measured in a well coun-
ter and corrected for decay. Activity concentrations in blood
vs. serum were compared using the individually determined
(clinical routine lab) hematocrit. Total blood volume was es-
timated from size, weight, and hematocrit.
The tracer biodistribution in patients was quantified by
SUVmean and SUVmax at 1 h and 3 h post injection. For cal-
culation of the standardized uptake value (SUV), circular re-
gions of interest were drawn around the area with focally
increased uptake in transaxial slices and automatically adapted
to a three-dimensional VOI with e.soft software (Siemens) at a
40 % isocontour. Primary tumors and lymph node metastases
were evaluated separately. The normal bladder (after voiding),
background (pelvic fat), blood, brain, salivary and lacrimal
glands, lung, liver, spleen, pancreas, small intestine, and kid-
neys were evaluated with a 2–3 cm sphere placed inside the
organ parenchyma.
Histopathological evaluation
Analyses of prostatectomy specimens were performed un-
der the supervision of dedicated uropathologists, using
International Society of Urological Pathology nomencla-
ture [28]. Pathologists were blinded to the PET/CT re-
sults. In addition, representative sections were stained
for immunohistochemistry. To accomplish this, sections
were deparaffinized in xylene and rehydrated in a graded
ethanol series. Antigen retrieval was performed with a
steam cooker using retrieval buffer (Target Retrieval
Solution, Dako). A mouse monoclonal antibody against
PSMA (clone 3E6, Dako) was used at a 1:100 dilution
and incubated overnight at 4 °C. Immunodetection was
performed using the Histostain-Plus detection kit
(Invitrogen) according to manufacturer’s recommenda-
t i ons . S t a ined sec t ions were scanned us ing a
Nanozoomer 2.0-HT Scansystem (Hamamatsu Photonics)
to generate digital whole slide images.
Results
Adverse events
All patients and healthy volunteers tolerated the examination
well. No drug-related pharmacological effects or physiologic
responses occurred. All observed parameters (e.g., blood pres-
sure, heart rate, body temperature) remained normal and un-
changed during and after the examination. No patient reported
subjective symptoms.
Radiation dosimetry
Maximum intensity projection (MIP) images of the serially
performed whole-body PET-scans of one healthy volunteer
are depicted in Fig. 2a and demonstrate distinct organ uptake
for lacrimal glands, salivary glands, liver, spleen, small intes-
tine and kidneys. The fitting of these organ VOIs and blood/
plasma samples are presented in Fig. 2b and c. According to
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the average of three healthy volunteers, the radiation dosime-
try revealed an effective dose of 0.022 mSv/MBq, i.e., 4.4–
5.5 mSv for an injected dose of 200–250 MBq. Mean values
of dedicated organ doses are presented in column 1 of Table 2.
The individual calculations of each subject’s organ absorbed
doses, effective half-lives and residence times are provided as
supplemental data. As a reference, Table 2 also presents the
corresponding organ absorbed doses for the other 18F-labelled
PSMA-ligands DCFPyL (column 5), DCFBC (column 6), the
68Ga-labelled compounds PSMA-11 (columns 2,3) and
PSMA-617 (column 4). In addition, the mean absorbed doses
for the submandibular glands were 0.075 mGy/MBq, parotid
glands 0.09 mGy/MBq and prostate gland 0.045 mGy/MBq.
The intra-individual dose ratios are very similar for all PSMA-
targeted agents; in comparison to 18F-DCFPyl, the effective
dose of 18F-PSMA-1007 is slightly higher, while lower clear-
ance through the urinary route reduces dose to the bladder
wall.
Normal-organ Biodistribution and tumor uptake
In healthy subjects, the blood pool contained mean 76,
22, 12 and 8 % of the injected dose at 2 min, 1 h, 2 h
and 3 h p.i., respectively. Approximately 95 % of the
blood pool activity was found in the serum; the blood
and serum curves converge with more complete clear-
ance. It is possible that there was a minimal and revers-
ible diffusion of the agent into blood cells; however,
irreversible binding to blood cells can be safely exclud-
ed. Clearance via the urinary tract was minimal and in
average only 1.2, 0.7 and 0.5 % of the injected activity
were eliminated in the urine during the 0–2, 2–4 and 4–
6 h intervals, respectively. In one healthy volunteer, sym-
metric tracer uptake (SUVmean 2, perfusion dependent
background <1) in the axillary lymph nodes was ob-
served. Taking into account his normal PSA-value and
an increased CRP and BSR (blood sedimentation rate),
this finding implies the potential of false-positive uptake
in inflammatory activated lymph nodes. The time-
activity-curve of the normal prostate tissue in the healthy
volunteers is provided in Fig. 3 and may serve as a
reference for future dynamic studies of primary prostate
cancer.
The uptakes in the primary tumor, lymph node metas-
tases and normal-organ biodistribution at 1 h and 3 h p.i.
in the ten patients with prostate cancer are presented in
Fig. 4. The mean tumor-uptake was 5- and 10-fold higher
at 1 h and 3 h p.i., compared to intra-vesical urine. The
Fig. 2 Maximum Intensity Projections (MIP) of ten serially performed
(5 min–8 h p.i.) 18F-PSMA-1007 PET-scans in one healthy volunteer (a);
biodistribution corrected for decay. Time-activity-curves of normal
organs derived from PET volume-of-interest (b). Blood and serum
time-activity-curves derived from serial blood-sampling, expressed as
percent injected dose in a total blood volume of 6.1 l (c)
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primary tumor was readily seen on PET-imaging in Fig. 5.
The intra-prostatic peak uptake correlated strongly with
the intraprostatic tumor mass as shown in Fig. 6.
Between 1 h and 3 h p.i. the absolute tumor uptake dem-
onstrated an increase in SUVmax and SUVmean by around
50 %. Simultaneously, the blood-pool declined by around
−40 %. Thus, the delineation of tumors improved at the
later time point at 3 h p.i. (Fig. 5) reaching an average
SUVmax of 41 in the primary tumors.
Correlation of imaging and post-surgery histopathology
The primary tumors and lymph node metastases were first
diagnosed on PET. Within a median of 20 days, eight
patients underwent radical prostatectomy and extended
pelvic lymphadenectomy (Table 1). Two patients had met-
astatic disease at initial diagnosis and did not undergo
surgery. In total 309 pelvic lymph nodes were histologi-
cally examined, out of which 290 were negative and 19
Table 2 Dosimetry (OLINDA) comparison of 18F-PSMA-1007 with other PSMA-targeted tracers
Absorbed Dose (mGy/MBq)
Organ 18F-PSMA-1007 68Ga-PSMA-11 68Ga-PSMA-11 68Ga-PSMA-617 18F-DCFPyL 18F-DCFBC
This work Afshar-Oromieh et al. [32] Pfob et al. [31] Afshar-Oromieh et al. [30] Szabo et al. [14] Cho et al. [13]
Adrenals 1.94E–02 1.42E–02 4.67E–03 1.48E–02 3.11E–02 1.85E–02
Brain 7.20E–03 9.00E–03 1.21E–03 3.53E–02 2.19E–03 4.21E–03
Breast 8.06E–03 8.80E–03 2.10E–03 1.03E–02 4.57E–03 8.51E–03
Gallbladder wall 2.22E–02 1.44E–02 4.23E–03 1.50E–02 1.44E–02 1.79E–02
Lower colon 4.83E–02 1.23E–02 4.64E–03 1.33E–02 1.05E–02 2.47E–02
Small intestine 1.56E–02 1.63E–02 3.64E–03 1.83E–02 9.13E–03 2.36E–02
Stomach 1.42E–02 1.20E–02 3.02E–03 1.30E–02 1.16E–02 3.02E–02
Upper colon 4.08E–02 5.40E–02 3.42E–03 4.48E–02 1.67E–02 2.34E–02
Heart wall 2.51E–02 1.09E–02 2.78E–03 1.20E–02 1.29E–02 2.92E–02
Kidneys 1.70E–01 2.62E–01 1.21E–01 2.06E–01 9.45E–02 2.84E–02
Liver 6.02E–02 3.09E–02 2.07E–02 2.88E–02 3.80E–02 2.46E–02
Lungs 1.11E–02 1.02E–02 7.89E–03 1.15E–02 1.08E–02 2.45E–02
Muscle 1.00E–02 1.05E–02 1.61E–03 1.15E–02 6.32E–03 9.69E–03
Pancreas 1.92E–02 1.38E–02 4.08E–03 1.45E–02 2.44E–02 1.92E–02
Red marrow 1.33E–02 9.20E–03 8.06E–03 1.00E–02 1.04E–02 1.70E–02
Osteogenic cells 1.55E–02 1.42E–02 6.77E–03 5.40E–02 9.58E–03 1.82E–02
Skin 7.30E–03 8.85E–02 2.09E–03 9.50E–03 4.05E–03 7.30E–03
Spleen 7.39E–02 4.46E–02 4.13E–02 2.85E–02 1.85E–02 1.72E–02
Testes 8.37E–03 1.04E–02 3.43E–03 1.15E–02 1.01E–02 1.54E–02
Thymus 9.90E–03 9.90E–03 2.22E–03 1.15E–02 5.56E–03 1.10E–02
Thyroid 8.50E–03 9.70E–03 2.14E–03 1.13E–02 8.56E–03 1.17E–02
Urinary bladder wall 1.87E–02 1.30E–01 1.64E–01 9.03E–02 8.64E–02 3.24E–02
ED
(mSv/MBq)
2.20E–02 2.36E–02 1.58E–02 2.08E–02 1.39E–02 1.99E–02
Fig. 3 Time-activity-curves of
18F-PSMA-1007 from a volume-
of-interest covering the healthy
prostate from three volunteers
(SUVmean with standard
deviations)
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were positive (median tumor diameter 5 mm; range 1–
18 mm). 18F-PSMA-1007 PET/CT demonstrated excellent
sensitivity (94.7 %). Overall, 18F-PSMA-1007 PET/CT
detected 18 of 19 lymph node metastases in the pelvis
including a node with a diameter as small as 1 mm. In
contrast to one healthy subject who was suspicious for
unspecific uptake in inflammatory lymph nodes, there
were no false-positive findings in the patient cohort
Fig. 4 a:Biodistribution of mean SUVmax of
18F-PSMA-1007 in normal
organs (blood, brain, nasal mucosa, lacrimal gland, parotid and
submandibularis glands, lungs, liver, spleen, pancreas, small intestines,
kidneys and bladder) and tumor lesions (prostate cancer (PCa) and lymph
node (LN) metastases) with its standard error. b: Biodistribution of mean
SUVmean of
18F-PSMA-1007 in normal organs (blood, brain, nasal
mucosa, lacrimal, parotid and submandibularis glands, lungs, liver,
spleen, pancreas, small intestines, kidneys and bladder) and tumor
lesions (prostate cancer (PCa) and lymph node (LN) metastases) with
its standard error. c: Biodistribution of mean SUVmax to background of
18F-PSMA-1007 in normal organs (blood, brain, nasal mucosa, lacrimal,
parotid and, submandibular glands, lungs, liver, spleen, pancreas, small
intestines, kidneys and bladder) and tumor lesions (prostate cancer (PCa)
and lymph node (LN) metastases) with its standard error
Fig. 5 a: Patient 2, a 72-year-old patient (PSA 15 ng/ml) diagnosed with
Gleason 9 (5 + 4) prostate cancer. Patient presented with a large tumor
mass in the prostate gland infiltrating the left seminal vesicle and
metastases to several lymph nodes in the pelvis. Two metastatic lymph
nodes are located outside the pelvis, both paraaortic at level L3/4 and L5.
18F-PSMA-1007 shows high tumor uptake after 1 h and 3 h p.i in the
maximum intensity projection PET-scan. Due to the lipophilic
characteristics of 18F-PSMA-1007, the hepatobiliary clearance can be
observed while urinary excretion is minimal. b: Patient 1, a 77-year-old
prostate cancer patient (PSA 40 ng/ml) shows a large tumor mass on the
mid and apical prostate and several lymph node metastases
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(specificity 100 %). Similarly, the peak intra-prostatic up-
take correlated with the main tumor mass (Fig. 6).
Positive PET-findings outside of the pelvis were not his-
topathologically validated.
Discussion
In this study we evaluated the radiation dosimetry,
biodistribution and preliminary efficacy of the new tracer,
18F-PSMA-1007.
Compared to other similar agents, the effective dose of 18F-
PSMA-1007 PET/CT (4.4–5.5 mSv for 200–250 MBq) was
comparable (Table 2). The effective organ half-life and, hence,
the exposure, depends primarily on the short physical half-life
of 18F rather than the biological half-life of the carrier
molecule. All Glu-urea-based PSMA-targeted tracers share a
similar physiological tracer distribution, thus the organ ratios
differ onlyminimally among the various ligands. One strength
of our dosimetry estimation is that we utilized a large number
of ten head-to-toe whole-body scans performed up to 6 h p.i.
(i.e. > 3 physical half-lives of 18F) allowing for excellent curve
fitting. One source of uncertainty is the limited number of
healthy subjects (n = 3). Nonetheless, since the normal organ
biodistribution of 18F-PSMA-1007 has proven highly similar
to other PSMA-targeted radiotracers, such as PSMA-11,
PSMA-617, DCFBC and DCFPyL [13, 14, 29, 30], we con-
sider that the results of this first dosimetry study are in keeping
with prior results. The performance of dosimetry in normal
volunteers is preferred to performing it in patients with large
tumor masses as these could cause tumor Bsink effects^
distorting the normal biodistribution. This has proven to be





CT-scan of patient 1 (a, b, e, f)
and corresponding histopatho-
logy of the subsequent prostatec-
tomy specimen; H&E staining
(c, g); PSMA-immunostaining
with outlined tumor contours in
red (d, h)
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less of a concern in PSMA ligands such as 18F-DCFPyL, in
which it was shown that the dosimetry in normal organs was
reliably assessed independently of the presence of tumor [14].
The average 1 h and 3 h SUVmax of
18F-PSMA-1007 in
tumor tissue, parotid glands, liver, kidneys and spleen can
be compared to data for PSMA-11 [9, 29] and PSMA-617
[30], because the evaluation of these 68Ga-labelled PSMA-
ligands were also performed at our institution with similar
imaging protocols, cross-calibrated scanners and analysis
software. In contrast, 18F-DCFBC and 18F-DCFPyL have
been evaluated with different scanners and imaging proto-
cols which makes the comparison less accurate. However,
even the comparison with PSMA-11 and PSMA-617 has
limitations. The low patient numbers might introduce er-
rors, especially on the highly variable inter-individual tu-
mor uptake. In addition, due to the higher positron energy
and increased spill-out-effects, 68Ga quantification might
be systematically underestimated in small lesions.
Furthermore, the patient selection differs: PSMA-617 was
evaluated in a heterogeneous group of patients [30], where-
as PSMA-11 was evaluated primarily in BCR patients [29].
In contrast PSMA-1007 is now evaluated in patients with
treatment-naive high-risk PCa. Therefore, quantification
per SUV should be interpreted cautiously. Semi-
quantitatively the ratio tumor-to-parotid is comparable for
all tracers. PSMA-617 has the lowest uptake in liver, kid-
ney and spleen, which was a goal when developing
theranostic PSMA-ligands for radionuclide therapy.
However, as known from 177Lu-PSMA-617 dosimetry
[15], PSMA-617 has slower tumor accumulation than
PSMA-11 and is considered suboptimal when used as
68Ga-labelled PET-tracer. 18F-PSMA-1007 shares the
slightly slower tracer kinetics of PSMA-617, although this
is less crucial due to the longer half-life of 18F in compar-
ison to 68Ga. Due to its structural similarity to PSMA-617,
it has been suggested that it could be an ideal diagnostic
surrogate for patients considering 177Lu-PSMA-617 thera-
py [18]. For a pure diagnostic tracer the slightly higher
uptake of 18F-PSMA-1007 in visceral organs is negligible
with regard to radiation burden and is also of limited clin-
ical impact as visceral metastases occur late in the course
of the disease. More importantly the increased uptake in
tumor tissue compared to other tracers improves tumor-to-
background ratios making it easier to detect small lymph
node metastases. It remains to be seen whether patients
with advanced castration-resistant PCa will have higher
liver background which may interfere with the detection
of metastases in comparison to the actual reference com-
pound 68Ga-PSMA-11. One clear advantage for local stag-
ing is that 18F-PSMA-1007 is temporarily retained in the
kidney parenchyma. For 18F-PSMA-1007, clearance via
the urinary tract was only 1.2 % injected activity during
0–2 h and another 0.7 % 2–4 h p.i.; in comparison, 11 % of
18F-DCFPyl is eliminated during the first 2 h via the uri-
nary tract and another 5 % until 3 h p.i. [14]. Bladder
content of up to SUVmax 40 (
68Ga-PSMA-617) and
SUVmax 100 (
68Ga-PSMA-11) has been reported for the
68Ga-containing compounds, respectively [29–32]. In con-
trast, the content of the urinary bladder was SUVmax 5 for
18F-PSMA-1007 (Fig. 4). Obviously, this agent demon-
strates delayed urinary excretion and thus fulfills some of
the design criteria for the ideal PSMA-targeted PET tracer.
This also explains the lower radiation dose to the urinary
bladder wall in comparison to other PSMA-tracers, while
kidney dose is comparable (Table 2).
In the evaluation of first patients, the sensitivity of 18F-
PSMA-1007 for small lymph node metastases was approxi-
mately 95 %. Metastatic nodes as small as 1 mm in diameter
were discovered. In a retrospective analysis of patients who
received pelvic lymphadenectomy after imaging with a varie-
ty of PSMA-targeted tracers, the sensitivity for these very
small nodes was limited [33]. Thus, small lesion detection is
a very promising early result for the new compound.
However, the mentioned study suffered from several limita-
tions, including a long interval between imaging and surgery
or the lack of standardization in regard to imaging protocols
and documentation of findings [33]. Therefore, it cannot be
concluded that the higher sensitivity in our cohort is caused
solely by the improved tracer. Nevertheless, lymph node me-
tastases with median diameters of 5 mm are close to the tech-
nical resolution limits of PET with 68Ga-PSMA tracers and,
therefore, it would be reasonable that 18F-PSMA tracers might
perform at a higher level.
Conclusion
18F-PSMA-1007 is an attractive alternative to 68Ga-PSMA-11
and 18F-DCFPyL. Radiation burden of a 200–250 MBq injec-
tion translates to 4.4–5.5 mSv effective dose, similar to other
established PET tracers. 18F-PSMA-1007 can be produced in
large amounts per batch in PET radiopharmacies with an on-
site cyclotron, reducing the demand for multiple tracer syn-
theses per day and enabling transfer to satellite centers.
Preliminary data suggest reduced urinary excretion and high
tumor to background ratios contribute to exceptional sensitiv-
ities including for tiny tumor deposits in the body. Larger trials
with this PET tracer are expected to further define its capabil-
ities and role in the management of prostate cancer.
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